{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T17:19:15Z","timestamp":1782580755074,"version":"3.54.5"},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T00:00:00Z","timestamp":1615420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI125160"],"award-info":[{"award-number":["R01AI125160"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI125160"],"award-info":[{"award-number":["R01AI125160"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272200800045C"],"award-info":[{"award-number":["HHSN272200800045C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>An estimated 10 million people developed tuberculosis (TB) disease in 2019 which underscores the need for a vaccine that prevents disease and reduces transmission. The aim of our current studies is to characterize and test a prophylactic tuberculosis vaccine comprised of ID93, a polyprotein fusion antigen, and a liposomal formulation [including a synthetic TLR4 agonist (glucopyranosyl lipid adjuvant, GLA) and QS-21] in a preclinical mouse model of TB disease. Comparisons of the ID93+GLA-LSQ vaccines are also made to the highly characterized ID93+GLA-SE oil-in-water emulsion adjuvant, which are also included these studies. The recent success of vaccine candidate M72 combined with adjuvant AS01<jats:sub>E<\/jats:sub> (GlaxoSmithKline Biologicals) in reducing progression to active disease is promising and has renewed excitement for experimental vaccines currently in the TB vaccine pipeline. The AS01<jats:sub>E<\/jats:sub> adjuvant contains monophosphoryl lipid A (MPL) and QS-21 (a saponin) in a liposomal formulation. While AS01<jats:sub>E<\/jats:sub> has demonstrated potent adjuvant activity as a component of both approved and experimental vaccines, developing alternatives to this adjuvant system will become important to fill the high demand envisioned for future vaccine needs. Furthermore, replacement sources of potent adjuvants will help to supply the demand of a TB vaccine [almost one-quarter of the world\u2019s population are estimated to have latent <jats:italic>Mycobacterium tuberculosis<\/jats:italic> (Mtb) according to the WHO 2019 global TB report], addressing (a) cost of goods, (b) supply of goods, and (c) improved efficacy of subunit vaccines against Mtb. We show that both ID93+GLA-SE (containing an emulsion adjuvant) and ID93+GLA-LSQ (containing a liposomal adjuvant) induce ID93-specific TH1 cellular immunity including CD4+CD44+ T cells expressing IFN\u03b3, TNF, and IL-2 (using flow cytometry and intracellular cytokine staining) and vaccine-specific IgG2 antibody responses (using an ELISA). In addition, both ID93+GLA-SE and ID93+GLA-LSQ effectively decrease the bacterial load within the lungs of mice infected with Mtb. Formulations based on this liposomal adjuvant formulation may provide an alternative to AS01 adjuvant systems.<\/jats:p>","DOI":"10.1371\/journal.pone.0247990","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T18:35:49Z","timestamp":1615487749000},"page":"e0247990","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":36,"title":["Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4543-9239","authenticated-orcid":true,"given":"Susan L.","family":"Baldwin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0847-7447","authenticated-orcid":true,"given":"Valerie A.","family":"Reese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha E.","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2693-7139","authenticated-orcid":true,"given":"Elyse","family":"Beebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9666-5397","authenticated-orcid":true,"given":"Jeff","family":"Guderian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T.","family":"Orr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6974-5666","authenticated-orcid":true,"given":"Rhea N.","family":"Coler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,3,11]]},"reference":[{"issue":"37","key":"pone.0247990.ref001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17370","article-title":"Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guerin vaccination against tuberculosis","volume":"17","author":"I Abubakar","year":"2013","journal-title":"Health Technol Assess"},{"issue":"7","key":"pone.0247990.ref002","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2471\/BLT.08.055657","article-title":"Disseminated bacille Calmette-Guerin disease in HIV-infected South African infants","volume":"87","author":"AC Hesseling","year":"2009","journal-title":"Bull World Health Organ"},{"issue":"6","key":"pone.0247990.ref003","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1086\/513642","article-title":"Disseminated bacille Calmette-Guerin disease after vaccination: case report and review","volume":"24","author":"EA Talbot","year":"1997","journal-title":"Clin Infect Dis"},{"issue":"17","key":"pone.0247990.ref004","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1803484","article-title":"Phase 2b Controlled Trial of M72\/AS01E Vaccine to Prevent Tuberculosis","volume":"379","author":"O Van Der Meeren","year":"2018","journal-title":"N Engl J Med"},{"issue":"25","key":"pone.0247990.ref005","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa1909953","article-title":"Final Analysis of a Trial of M72\/AS01E Vaccine to Prevent Tuberculosis","volume":"381","author":"DR Tait","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0247990.ref006","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1208\/s12249-016-0688-7","article-title":"Lyophilization of an Adjuvanted Mycobacterium tuberculosis Vaccine in a Single-Chamber Pharmaceutical Cartridge","volume":"18","author":"VL Barnes","year":"2017","journal-title":"AAPS PharmSciTech"},{"key":"pone.0247990.ref007","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jconrel.2013.12.025","article-title":"Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilization","volume":"177","author":"MT Orr","year":"2014","journal-title":"J Control Release"},{"issue":"1","key":"pone.0247990.ref008","doi-asserted-by":"crossref","first-page":"e16333","DOI":"10.1371\/journal.pone.0016333","article-title":"Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant","volume":"6","author":"RN Coler","year":"2011","journal-title":"PLoS One"},{"issue":"9","key":"pone.0247990.ref009","doi-asserted-by":"crossref","first-page":"eaas9930","DOI":"10.1126\/sciadv.aas9930","article-title":"The adjuvant GLA-AF enhances human intradermal vaccine responses","volume":"4","author":"D Carter","year":"2018","journal-title":"Sci Adv"},{"key":"pone.0247990.ref010","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41541-018-0057-5","article-title":"The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial","volume":"3","author":"RN Coler","year":"2018","journal-title":"NPJ Vaccines"},{"issue":"9","key":"pone.0247990.ref011","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1093\/cid\/ciy1140","article-title":"First-in-human, Randomized, Double-blind Clinical Trial of Differentially Adjuvanted PAMVAC, A Vaccine Candidate to Prevent Pregnancy-associated Malaria","volume":"69","author":"B Mordmuller","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"4","key":"pone.0247990.ref012","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2213-2600(18)30077-8","article-title":"Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial","volume":"6","author":"A Penn-Nicholson","year":"2018","journal-title":"Lancet Respir Med."},{"issue":"4","key":"pone.0247990.ref013","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.vaccine.2015.10.027","article-title":"Schistosomiasis vaccine candidate Sm14\/GLA-SE: Phase 1 safety and immunogenicity clinical trial in healthy, male adults","volume":"34","author":"M Santini-Oliveira","year":"2016","journal-title":"Vaccine"},{"issue":"53","key":"pone.0247990.ref014","doi-asserted-by":"crossref","first-page":"53ra74","DOI":"10.1126\/scitranslmed.3001094","article-title":"A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis","volume":"2","author":"S Bertholet","year":"2010","journal-title":"Sci Transl Med"},{"issue":"4","key":"pone.0247990.ref015","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1164\/rccm.201208-1385OC","article-title":"Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72\/AS01 in South African adults","volume":"188","author":"CL Day","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"pone.0247990.ref016","doi-asserted-by":"crossref","first-page":"152905","DOI":"10.1016\/j.phymed.2019.152905","article-title":"Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review","volume":"60","author":"MA Lacaille-Dubois","year":"2019","journal-title":"Phytomedicine"},{"issue":"3","key":"pone.0247990.ref017","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.coi.2012.03.008","article-title":"Adjuvants for human vaccines","volume":"24","author":"CR Alving","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"pone.0247990.ref018","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.colsurfb.2013.09.006","article-title":"In vitro evaluation of TLR4 agonist activity: formulation effects","volume":"113","author":"A Misquith","year":"2014","journal-title":"Colloids Surf B Biointerfaces"},{"key":"pone.0247990.ref019","doi-asserted-by":"crossref","first-page":"461705","DOI":"10.1016\/j.chroma.2020.461705","article-title":"A Two-Step Orthogonal Chromatographic Process for Purifying the Molecular Adjuvant QS-21 with High Purity and Yield","volume":"1635","author":"Y Qi","year":"2021","journal-title":"J Chromatogr A"},{"issue":"1","key":"pone.0247990.ref020","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jconrel.2013.07.030","article-title":"Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis","volume":"172","author":"MT Orr","year":"2013","journal-title":"J Control Release"},{"issue":"2","key":"pone.0247990.ref021","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/BF00395856","article-title":"The mouse Igh-1a and Igh-1b H chain constant regions are derived from two distinct isotypic genes","volume":"29","author":"E Jouvin-Marche","year":"1989","journal-title":"Immunogenetics"},{"issue":"2","key":"pone.0247990.ref022","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0022-1759(98)00015-5","article-title":"The need for IgG2c specific antiserum when isotyping antibodies from C57BL\/6 and NOD mice","volume":"212","author":"RM Martin","year":"1998","journal-title":"J Immunol Methods"},{"issue":"7","key":"pone.0247990.ref023","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.4049\/jimmunol.1501118","article-title":"Vaccination Produces CD4 T Cells with a Novel CD154-CD40-Dependent Cytolytic Mechanism","volume":"195","author":"RN Coler","year":"2015","journal-title":"J Immunol"},{"issue":"2","key":"pone.0247990.ref024","doi-asserted-by":"crossref","first-page":"614","DOI":"10.4049\/jimmunol.174.2.614","article-title":"Cutting edge: MHC class II-restricted killing in vivo during viral infection","volume":"174","author":"ER Jellison","year":"2005","journal-title":"J Immunol"},{"issue":"5","key":"pone.0247990.ref025","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.4049\/jimmunol.1102696","article-title":"The importance of adjuvant formulation in the development of a tuberculosis vaccine","volume":"188","author":"SL Baldwin","year":"2012","journal-title":"J Immunol"},{"issue":"2","key":"pone.0247990.ref026","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1128\/CVI.00458-15","article-title":"Protection and Long-Lived Immunity Induced by the ID93\/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate","volume":"23","author":"SL Baldwin","year":"2016","journal-title":"Clin Vaccine Immunol."},{"key":"pone.0247990.ref027","first-page":"105","volume-title":"Immunopotentiators in Modern Vaccines","author":"C.B. Fox DC","year":"2017","edition":"2"},{"issue":"4","key":"pone.0247990.ref028","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.4049\/jimmunol.1400948","article-title":"Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells","volume":"193","author":"AM Didierlaurent","year":"2014","journal-title":"J Immunol"},{"issue":"1","key":"pone.0247990.ref029","doi-asserted-by":"crossref","first-page":"e0146372","DOI":"10.1371\/journal.pone.0146372","article-title":"The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for TH1 Induction","volume":"11","author":"N Dubois Cauwelaert","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"pone.0247990.ref030","doi-asserted-by":"crossref","first-page":"15560","DOI":"10.1038\/s41598-019-52146-0","article-title":"Long-term protective efficacy with a BCG-prime ID93\/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model","volume":"9","author":"KW Kwon","year":"2019","journal-title":"Sci Rep"},{"key":"pone.0247990.ref031","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41541-017-0027-3","article-title":"Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNgamma response promoting vaccine immunogenicity","volume":"2","author":"M Coccia","year":"2017","journal-title":"NPJ Vaccines"},{"issue":"1","key":"pone.0247990.ref032","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","article-title":"Adjuvant system AS01: helping to overcome the challenges of modern vaccine","volume":"16","author":"AM Didierlaurent","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"pone.0247990.ref033","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3389\/fimmu.2018.00564","article-title":"Adjuvant-Associated Peripheral Blood mRNA Profiles and Kinetics Induced by the Adjuvanted Recombinant Protein Candidate Tuberculosis Vaccine M72\/AS01 in Bacillus Calmette-Guerin-Vaccinated Adults","volume":"9","author":"RA van den Berg","year":"2018","journal-title":"Front Immunol."},{"issue":"2","key":"pone.0247990.ref034","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cell.2016.08.072","article-title":"A Functional Role for Antibodies in Tuberculosis","volume":"167","author":"LL Lu","year":"2016","journal-title":"Cell"},{"issue":"10","key":"pone.0247990.ref035","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/nbt1015-1015","article-title":"Landmark green light for Mosquirix malaria vaccine","volume":"33","author":"C Morrison","year":"2015","journal-title":"Nat Biotechnol"},{"issue":"1","key":"pone.0247990.ref036","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/imr.12276","article-title":"B cells and antibodies in the defense against Mycobacterium tuberculosis infection","volume":"264","author":"JM Achkar","year":"2015","journal-title":"Immunol Rev"},{"issue":"6","key":"pone.0247990.ref037","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.smim.2014.10.005","article-title":"The role of B cells and humoral immunity in Mycobacterium tuberculosis infection","volume":"26","author":"J Chan","year":"2014","journal-title":"Semin Immunol"},{"key":"pone.0247990.ref038","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3389\/fimmu.2020.00226","article-title":"Thinking Outside the Box: Innate- and B Cell-Memory Responses as Novel Protective Mechanisms Against Tuberculosis","volume":"11","author":"JA Choreno-Parra","year":"2020","journal-title":"Front Immunol."},{"issue":"14","key":"pone.0247990.ref039","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.137858","article-title":"Pulmonary Mycobacterium tuberculosis control associates with CXCR3- and CCR6-expressing antigen-specific Th1 and Th17 cell recruitment","volume":"5","author":"U Shanmugasundaram","year":"2020","journal-title":"JCI Insight."},{"issue":"5","key":"pone.0247990.ref040","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/14760584.2019.1593143","article-title":"Designing tuberculosis vaccine efficacy trials\u2014lessons from recent studies","volume":"18","author":"AM Ginsberg","year":"2019","journal-title":"Expert Rev Vaccines"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0247990","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T18:36:28Z","timestamp":1615487788000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0247990"}},"subtitle":[],"editor":[{"given":"Angelo A.","family":"Izzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,3,11]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0247990","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,11]]}}}